氨甲西平 | 60575-32-8

• 物质功能分类: 原料药 - 解热镇痛药 - 解热止痛药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 氨甲西平
• 英文名称: Amezepine
• 英文别名: N-methyl-2-(11-methylbenzo[b][1]benzazepin-5-yl)ethanamine
• CAS: 60575-32-8
• 化学式: C₁₈H₂₀N₂
• 分子量: 264.37
• InChiKey: MHBXHCOUWYQAFZ-UHFFFAOYSA-N

物化性质

• 沸点：
  411.6±34.0 °C(Predicted)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  草酸 、 氨甲西平 在 氢溴酸 作用下， 以40%的产率得到2-(11H-benzo[b][1]benzazepin-5-yl)-N-methylethanamine;oxalic acid
  参考文献：
  名称：

  Allais; Guillaume; Poittevin, European Journal of Medicinal Chemistry, 1982, vol. 17, # 4, p. 371 - 381

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl N-methyl-N-[2-(11-methylbenzo[b][1]benzazepin-5-yl)ethyl]carbamate 在 氢氧化钾 作用下， 以 正丁醇 为溶剂， 反应 20.0h， 以2.65 g的产率得到氨甲西平
  参考文献：
  名称：

  Allais; Guillaume; Poittevin, European Journal of Medicinal Chemistry, 1982, vol. 17, # 4, p. 371 - 381

  摘要：

  DOI：

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Fast-dispersing dosage form containing 5-HT1 agonists
  申请人：——

  公开号：US20040023948A1

  公开（公告）日：2004-02-05

  This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT 1 agonist, characterized in that the composition is formulated to reduce pre-systemic metabolism of said 5-HT 1 agonist. A process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders and/or as a memory enhancer are also provided.

  本发明涉及一种口服药物组合物，该组合物由载体和作为活性成分的 5-HT 1 激动剂，其特征在于该组合物的配制可减少所述 5-HT 1 激动剂。本发明还提供了制备这种组合物的工艺以及这种组合物用于治疗焦虑症、抑郁症、注意力缺陷障碍和/或恐慌症和/或作为记忆增强剂的用途。
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• Method and Compositions for Treating Cancer and Related Methods
  申请人：Narla Goutham

  公开号：US20120322792A1

  公开（公告）日：2012-12-20

  The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib a tricyclic agent compound, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib, and wherein the tricyclic agent is administered in an amount that does not lead to a substantial central nervous system effect. In additional aspects, the invention relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy.